Cited by 3Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Preparation of antibodies against TXR1 and construction of a new DNA tumor vaccine

Sun, Yuanjie, Zhang, Xiyang, Yang, Shuya, Hu, Chenchen, Pan, Jingyu, Liu, Tianyue, Ding, Jiaqi, Han, Chenying +2 more·2022·International Immunopharmacology

Abstract

Background Taxol-resistance gene 1 (TXR1) is closely correlated with the paclitaxel resistance in the cancer chemotherapy. However, due to the lack of monoclonal antibodies (mAbs) with strong specificity and high sensitivity, little information is found about TXR1 target-related tumor therapy.Methods We developed an TXR1 recombinant DNA vaccine by inserting TXR1 DNA sequence into lysosome-associated membrane protein 1 (LAMP1). Adaptive immune responses were assessed by indirect enzyme-linked immunosorbent assay (ELISA), Enzyme-linked immunospot test (ELISpot), and cytotoxic T-lymphocyte (CTL) cytotoxicity.Results The pGEX4T-1-TXR1 reconstructed prokaryotic expression plasmid was constructed for producing high-purity TXR1 protein. Subsequently, a total of four mAbs for TXR1 and two PcAbs were successfully constructed and identified. We further found that TXR1 was highly expressed in breast cancer tissue than normal controls. Therefore, we constructed four tumor vectors, pVAX1-LAMP/TXR1, pVAX1-LAMP, pVAX1/TXR1 and pVAX1, for immunization. After three times of immunization, ELISpot data showed that single peptide 6,9,11 could stimulate T cells secreting IFN-γ in pVAX1-LAMP/TXR1 group. Moreover, the number of specific T cells and immune response effects significantly increased comparing to the pVAX1-LAMP control group. In addition, cytotoxicity showed that when the effect to target ratio was 40:l the killing effect of pVAX1-LAMP/TXR1 group was significantly higher than the pVAX1-TXR1 group.Conclusion Our results provides new evidence for the TXR1 related tumor immunology and aids the early prevention of cancer.

Integrity signals

Registry

Crossref · 10.1016/j.intimp.2021.108505

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

2 retracted

Flagged first, then by citations

1 of the 35 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sun, Y., Zhang, X., Yang, S., Hu, C., Pan, J., Liu, T., Ding, J., Han, C., Huang, Y., & Yang, K.
Affiliations
Air Force Medical University (CN)
Corresponding author
Yang, Kun
Venue
International Immunopharmacology
Publisher
Elsevier BV
Published
2022-02
Volume
103
Pages
108505
ISSN
1567-5769 (ISSN-L)
OpenAlex
W4206376958
Cited by
3
References
35
Citations by year
2023: 1 · 2022: 2
FWCI
0.29
Type
journal article
Language
en
Open access
closed
Locations
  • International Immunopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (82073154, 82103461)
  • Natural Science Foundation of Shaanxi Province (2021SF-114)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords
paclitaxel resistance, monoclonal antibodies, polyclonal antibodies, DNA vaccine, recombinant protein expression, breast cancer, cytotoxic T lymphocytes, IFN-gamma secretion, tumor immunology
MeSH terms
Animals, Antibodies, Viral, DNA, Humans, Mice, Inbred BALB C, Neoplasms, Vaccines, DNA, Cancer Vaccines, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review